Three patients are fully recovered from cancer as per the below report using CAR-T therapy in India developed by ImmunoAct where Laurus Labs has 33.86% stake.

What is CAR-T Therapy That Made A 6-Year-Old Cancer Free? | 8x Cheaper Than Other Cancer Cures

PEB in the US versus doing PBS in India?

It’s 15% versus 28% (Contribution margins). From an EBIT point of view, we expect going forward about 10% in India and about 15% in the US for the metal building business.

US market leader in this space : Cornerstone or Ukor. They usually do 6%-8% EBIT margins.

For Pennar :

And our engineering is all done in India for that. While we have our design teams there, most of the high manners get done in India. And there’s significant cost arbitrage based on that.

Another reason why our margin would be a little bit better than their margins would be the fact that we can also backward integrate into other metal products. So our more diverse steel buying experience also gives us an additional margin.

Lower Cost Advantage for Pennar vs Market leaders in PEB

Royal Orchid Hotels –

Q3 Concall highlights –

Revenues – 87 vs 76 cr

EBITDA – 29 vs 28 cr

PAT – 15.7 vs 15.2 cr

Revenue break up ( segment wise ) –

Room rent – 46 vs 43 cr

F&B – 33 vs 28 cr

Other services – 3.6 vs 2.8 cr

Management fees – 8 vs 6 cr

Revenue break up ( model wise ) –

Owned hotels – 30 vs 24 cr

Leased / revenue share hotels – 34 vs 27 cr

JVs / Associates – 18 vs 23 cr

Management fees – 8 vs 6 cr

Added 05 hotels with 210 rooms in Q3. Added 20 hotels with 1030 rooms in 9M FY 24

Company held 51 pc stake in a 130 room hotel in Bangalore. Acquired additional 49 pc stake by paying 34 cr in Q3. The money was paid via internal cash generation

Out of a total of 100 hotels that the company is operating, around 80 odd hotels are just being managed by the company. Here, the company gets a management fees of around 3 pc of the property’s revenue. For Q3, total revenue received by the company from management contracts is 8 cr for managing 80 hotels. That amounts to roughly 3.5 lakh / month / hotel. Company makes an EBITDA of around 50 pc on these properties

Expecting to do a topline of 340 cr this yr and 390 cr for next FY ( both – including the Jaipur hotel ). Expecting an EBITDA of 120 cr for next FY

Company intends to add 38-40 more hotels in next FY – adding the room inventory by around 2500 rooms. Out of these, 03 hotels will be on the lease / revenue share model – which gives a bigger kick to the top/bottom line

ARRs for Q3 at Rs 5600

Post Mar 25, company shall focus on larger hotels on revenue share models. Company’s aim was to expand aggressively in FY23-25 period so as to establish its brand name. Once that is done, company can get hold of a lot more leased / revenue share hotels ( otherwise, ppl were not taking them as seriously )

Hotel industry is undergoing a boom similar to 2003-08. Bank financing rates have also fallen while extending loans to Hotel industry

Company intends to re-work their branding architecture so as to clearly differentiate between their 5 star vs 3 star offerings

Expecting an ARR hike of 6-8 pc for next FY

Company is expanding the room capacity at their owned hotels at Goa ( adding 44 rooms ), Bengaluru ( adding 28 rooms )

Company is expanding the room capacity at their owned hotels at Goa ( adding 44 rooms ), Bengaluru ( adding 28 rooms )

At present, company is not planning to open up at Ayodhya or Lakshadweep as the company doesn’t want to do any Greenfield capex right now

Disc: holding, biased, not SEBI registered

Delhivery management seems determined to improve their share in standard PTL space. They intend to stay the least cost operator by absorbing the impact of general inflation, leveraging the exceptional incremental gross margin of the network.

Curious case of Orchid Pharma

15,376% Returns Bizarre

Orchid Pharma got listed on 3rd November 2020 @Rs 17.15 and it grew to ATH Rs 2654.25 in the span of 4-5 Months.

March 2017 went to NCLAT – Dhanuka Labs took over – 98% of shareholding of Orchid Pharma – Retail investors who had invested in Orchid pharma were alotted 1 share for every 218 shares they were holding. (217 taken away)

Entity had special treatment and they were holding 98% but with condition that they have to reduce their holding to 75% (which is usually the norm for listed company in india)

Story:

0.5% shares were traded in the market as this was the float at that time.
(2,06,480 shares only)
Scarcity of shares caused price surge. Seeing the price rise others got interested too. Demand for the shares increased leading to further stock price rise.
There were negligible people who were willing to sell and plenty of buyers leading to stock price rise. 5% circuit happened for several 100 consecutive days.

Ruchi soya once more.

SEBI revised the norms after this – Back from the death share holding companies will need to have 5% public shareholding at the time of listing. No more super small shareholding gimmicks. Well.